Dr. Rocconi on the Impact of the SORAYA Trial in FRα+ Ovarian Cancer Treatment
In Partnership With:
Rodney Rocconi, MD, discusses the impact of the phase 3 SORAYA trial in folate receptor alpha–positive ovarian cancer.
Rodney Rocconi, MD, professor, gynecologic oncology, associate director, Gynecologic Oncology, associate director, Infirmary Cancer Care, director, Research at Infirmary Cancer Care, the O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, discusses the impact of the phase 3 SORAYA trial (NCT04296890) in folate receptor alpha (FRα)–positive ovarian cancer.
The phase 3 trial evaluated the safety and efficacy of the novel antibody-drug conjugate, mirvetuximab soravtansine (IMGN853).
Single-agent mirvetuximab soravtansine was evaluated in comparison with investigator’s choice of chemotherapy on the trial, Rocconi states. All patients were required to have received prior bevacizumab (Avastin) and have prior resistance to platinum-based chemotherapy with a progression-free interval of less than 6 months, Rocconi explains. Patients previously treated with PARP inhibitors were also permitted to enroll on the trial, Rocconi adds.
Other agents investigated in the platinum-resistant setting have historically shown produce low objective response rates (ORR), Rocconi continues. However, the efficacy data from the SORAYA trial showed significant increases in both ORR and duration of response, Rocconi explains.
Improvements in patient responses suggest mirvetuximab soravtansine is a promising treatment option for this patient population, Rocconi concludes.
